These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 29587555

  • 1. Discovery and development of varenicline for smoking cessation.
    Jordan CJ, Xi ZX.
    Expert Opin Drug Discov; 2018 Jul; 13(7):671-683. PubMed ID: 29587555
    [Abstract] [Full Text] [Related]

  • 2. Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis.
    Thomas KH, Dalili MN, López-López JA, Keeney E, Phillippo D, Munafò MR, Stevenson M, Caldwell DM, Welton NJ.
    Health Technol Assess; 2021 Oct; 25(59):1-224. PubMed ID: 34668482
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial.
    Benowitz NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, Lawrence D, St Aubin L, Anthenelli RM.
    JAMA Intern Med; 2018 May 01; 178(5):622-631. PubMed ID: 29630702
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological interventions for smoking cessation: an overview and network meta-analysis.
    Cahill K, Stevens S, Perera R, Lancaster T.
    Cochrane Database Syst Rev; 2013 May 31; 2013(5):CD009329. PubMed ID: 23728690
    [Abstract] [Full Text] [Related]

  • 5. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.
    Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, Ascher J, Russ C, Krishen A, Evins AE.
    Lancet; 2016 Jun 18; 387(10037):2507-20. PubMed ID: 27116918
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Nicotine receptor partial agonists for smoking cessation.
    Cahill K, Stead LF, Lancaster T.
    Cochrane Database Syst Rev; 2010 Dec 08; (12):CD006103. PubMed ID: 21154363
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Modelling continuous abstinence rates over time from clinical trials of pharmacological interventions for smoking cessation.
    Jackson SE, McGowan JA, Ubhi HK, Proudfoot H, Shahab L, Brown J, West R.
    Addiction; 2019 May 08; 114(5):787-797. PubMed ID: 30614586
    [Abstract] [Full Text] [Related]

  • 11. Nicotine receptor partial agonists for smoking cessation.
    Cahill K, Stead LF, Lancaster T.
    Cochrane Database Syst Rev; 2008 Jul 16; (3):CD006103. PubMed ID: 18646137
    [Abstract] [Full Text] [Related]

  • 12. Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.
    Keating GM, Lyseng-Williamson KA.
    Pharmacoeconomics; 2010 Jul 16; 28(3):231-54. PubMed ID: 20108995
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Nicotine receptor partial agonists for smoking cessation.
    Cahill K, Stead LF, Lancaster T.
    Cochrane Database Syst Rev; 2007 Jan 24; (1):CD006103. PubMed ID: 17253581
    [Abstract] [Full Text] [Related]

  • 16. Pharmacovigilance Assessment of Cardiac Implications of Nicotine Replacement Therapy Among Smokers.
    Olawuyi O, Mathieson K.
    Curr Drug Saf; 2020 Jan 24; 15(3):173-180. PubMed ID: 32525783
    [Abstract] [Full Text] [Related]

  • 17. [Smoking cessation: Pharmacological strategies different from standard treatments].
    Underner M, Perriot J, Peiffer G, Harika-Germaneau G, Jaafari N.
    Rev Pneumol Clin; 2018 Sep 24; 74(4):205-214. PubMed ID: 29773262
    [Abstract] [Full Text] [Related]

  • 18. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
    Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR, Varenicline Phase 3 Study Group.
    JAMA; 2006 Jul 05; 296(1):47-55. PubMed ID: 16820546
    [Abstract] [Full Text] [Related]

  • 19. Frequently Reported Adverse Events With Smoking Cessation Medications: Post Hoc Analysis of a Randomized Trial.
    Ebbert J, Jimenez-Ruiz C, Dutro MP, Fisher M, Li J, Hays JT.
    Mayo Clin Proc; 2021 Jul 05; 96(7):1801-1811. PubMed ID: 34112520
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.